On December 18, 2024, Shkreli posted the following on X (formerly Twitter):
"Galectin Therapeutics ( $GALT ) is developing belapectin for NASH. Galectin has said it will release the results of its "NAVIGATE" Phase II/III study by December. This trial will fail and GALT stock will plummet. GALT has enough cash to last until May."
Shkreli is well known for his intimate knowledge of the pharmaceutical industry and the mechanisms of drug studies / trials. He is also well known for speculating on bio / pharmaceutical stocks.
Previously, Shkreli publicly predicted the failure of Cassava Sciences ($SAVA) Phase 3 Alzheimers trial which precipitated the stocks 80% fall.
Will Shkreli successfully predict the failure of Galectin's "NAVIGATE" study?
Question will resolve to "Yes" if, before 2026, there are credible reports that:
Galectin Therapeutics NAVIGATE" Phase II/III study fails, AND
Galectin Therapeutics stock, $GALT, plummets due to the study failure.
If the study is delayed to 2026, the question will be resolved to "N/A".
1,000🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ267 | |
| 2 | Ṁ76 | |
| 3 | Ṁ46 | |
| 4 | Ṁ31 |
"Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis."
"Galectin Therapeutics’ stock is down over 35% in premarket trading Friday morning after its lead asset failed to reach its primary endpoint for patients with a form of liver cirrhosis."
$GALT down 56% today